hotspot -WSS

hotspot

author：comprehensive 2025-08-23 18:37:56 - browse：16

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Pumping milk in bathrooms at health conferences is common

hotspot

WSS

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Cue Health, Covid

Inaction leaves children at risk from dangerous chemotherapy drug

Inaction leaves children at risk from dangerous chemotherapy drug

HPV vaccine, cervical cancer study delivers historic results

Microsoft launches AI tool for clinical documentation through Epic

leisure time

hotspot

Bluebird and the case for gene therapy profits

hotspot

Medical leaders decry Supreme Court decision on affirmative action

For longer

After affirmative action ruling, medical educators look to 'holistic review'

FDA sets aggressive timeline for overhauling inspection procedures

Virginia high school admissions case could be legal follow

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Drug repurposing or repositioning? The language matters

Reports of telehealth's death have been greatly exaggerated

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Digital health: a case of mistaken identity

hotspot

UnitedHealth argues against case alleging wrongful AI care denials

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Investigation reveals sickle cell patients pressured into sterilizations

Medicare drug price lawsuits could be good politics for Biden

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

entertainment

hotspot

leisure time

leisure time